Your browser doesn't support javascript.
Sero-Prevalence and Sero-Incidence of Antibodies to SARS-CoV-2 in Health Care Workers in Israel, Prior to Mass COVID-19 Vaccination.
Muhsen, Khitam; Schwaber, Mitchell J; Bishara, Jihad; Kassem, Eias; Atamna, Alaa; Na'amnih, Wasef; Goren, Sophy; Bialik, Anya; Mohsen, Jameel; Zaide, Yona; Hazan, Nimrod; Ariel-Cohen, Ortal; Cohen, Regev; Shitrit, Pnina; Marchaim, Dror; Benenson, Shmuel; Ben-David, Debby; Rubinovitch, Bina; Gotessman, Tamar; Nutman, Amir; Wiener-Well, Yonit; Maor, Yasmin; Carmeli, Yehuda; Cohen, Dani.
  • Muhsen K; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Schwaber MJ; National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel.
  • Bishara J; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kassem E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Atamna A; Infectious Diseases Unit, Rabin Medical Centre, Beilinson Hospital, Petah-Tiqva, Israel.
  • Na'amnih W; Department of Pediatrics, Hillel Yaffe Medical Centre, Hadera, Israel.
  • Goren S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Bialik A; Infectious Diseases Unit, Rabin Medical Centre, Beilinson Hospital, Petah-Tiqva, Israel.
  • Mohsen J; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Zaide Y; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hazan N; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ariel-Cohen O; Department of Cardiology, Hillel Yaffe Medical Centre, Hadera, Israel.
  • Cohen R; American Medical Laboratories, Herzlya, Israel.
  • Shitrit P; American Medical Laboratories, Herzlya, Israel.
  • Marchaim D; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Benenson S; Infection Control Unit, Sanz Medical Centre, Netanya, Israel.
  • Ben-David D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Rubinovitch B; Infection Control Unit, Meir Medical Centre, Kefar Saba, Israel.
  • Gotessman T; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Nutman A; Infection Control Unit, Shamir (Assaf Harofeh) Medical Centre, Be'er Ya'akov, Israel.
  • Wiener-Well Y; Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
  • Maor Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Carmeli Y; Infection Control Unit, Wolfson Medical Centre, Wolfson, Israel.
  • Cohen D; Infection Control Unit, Beilinson Hospital, Rabin Medical Centre, Petah-Tiqva, Israel.
Front Med (Lausanne) ; 8: 689994, 2021.
Article in English | MEDLINE | ID: covidwho-1305656
ABSTRACT

Objectives:

This study aims to examine the prevalence and risk factors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sero-positivity in health care workers (HCWs), a main risk group, and assess the sero-incidence of SARS-CoV-2 infection between the first and second waves of coronavirus disease 2019 (COVID-19) in Israel.

Methods:

A longitudinal study was conducted among 874 HCWs from nine hospitals. Demographics, health information, and blood samples were obtained at baseline (first wave-April-May 2020) and at follow-up (n = 373) (second wave-September-November 2020). Sero-positivity was determined based on the detection of total antibodies to the nucleocapsid antigen of SARS-CoV-2, using electro-chemiluminescence immunoassay (Elecsys® Anti-SARS-CoV-2, Roche Diagnostics, Rotkreuz, Switzerland).

Results:

The sero-prevalence of SARS-CoV-2 antibodies was 1.1% [95% confidence intervals (CI) 0.6-2.1] at baseline and 8.3% (95% CI 5.9-11.6) at follow-up. The sero-conversion of SARS-CoV-2 serum antibody was 6.9% (95% CI 4.7-9.9) during the study period. The increase in SARS-CoV-2 sero-prevalence paralleled the rise in PCR-confirmed SARS-CoV-2 infections among the HCWs across the country. The likelihood of SARS-CoV-2 sero-prevalence was higher in males vs. females [odds ratio (OR) 2.52 (95% CI 1.05-6.06)] and in nurses vs. physicians [OR 4.26 (95% CI 1.08-16.77)] and was associated with being quarantined due to exposure to COVID-19 patients [OR 3.54 (95% CI 1.58-7.89)] and having a positive PCR result [OR 109.5 (95% CI 23.88-502.12)].

Conclusions:

A significant increase in the risk of SARS-CoV-2 infection was found among HCWs between the first and second waves of COVID-19 in Israel. Nonetheless, the sero-prevalence of SARS-CoV-2 antibodies remains low, similar to the general population. Our findings reinforce the rigorous infection control policy, including quarantine, and utilization of personal protective equipment that should be continued together with COVID-19 immunization in HCWs and the general population.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.689994

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Front Med (Lausanne) Year: 2021 Document Type: Article Affiliation country: Fmed.2021.689994